INTIMATION UNDER REGULATION 57(5) AT THE END OF THE QUARTER 30.09.2025 (NON APPLICABILITY CERTIFICATE)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs has filed a non-applicability certificate with BSE under Regulation 57(5) for the quarter ended September 30, 2025. The regulation, which requires listed entities to report interest, dividend, and principal payments on non-convertible securities, does not apply to the company because it has no such securities outstanding. The company confirms there were no payments of interest, dividend, or principal due during the quarter. The filing is signed by Chairman and Director Sudhir Sethi.
No material impact on shareholders or stock price. This is a routine procedural compliance filing that confirms the absence of any non-convertible debt obligations, signalling no debt servicing events during the quarter.